News & Updates
Filter by Specialty:
QoL preserved in patients with refractory mCRC treated with add-on bevacizumab
26 Aug 2023
byJairia Dela Cruz
In the treatment of refractory metastatic colorectal cancer (mCRC), the addition of bevacizumab to trifluridine/tipiracil (FTD/TPI) does not appear to hurt the quality of life (QoL), with patients receiving add-on bevacizumab being able to maintain their QoL for a longer period than those receiving FTD/TPI monotherapy, according to a post hoc analysis of the phase III SUNLIGHT trial.
QoL preserved in patients with refractory mCRC treated with add-on bevacizumab
26 Aug 2023Older age at first screening colonoscopy linked to higher risk of adenomas, CRC
25 Aug 2023
At a first screening colonoscopy, older patients are more likely to have a detection of adenomatous polyps and colorectal cancer (CRC), reveals a study.